General Information
Version
1.30
Revision date
2015-04-21
Product name
REMICADE
Substance name
REMICADE 100mg lyophilized powder for IV infusion infliximab
1.2.1 Relevant identified uses
Finished Pharmaceutical Product
supplier name
Janssen Pharmaceuticals, Inc
Emergency telephone
+32 14 60 24 44
Icons in SDS
Company Information
company name
Janssen Pharmaceuticals, Inc
e-mail address of the competent person responsible for the Safety Data Sheet
SDSJanssen@its.jnj.com
Section 2
SECTION 2: Hazards identification
GHS Classification GHS Classification Not a hazardous substance or mixture
2.2 Label elements
Not a hazardous substance or mixture., Medicinal products in the finished state, intended for the final user, are not subject to GHS labeling.
2.3 Other hazards
This Finished Pharmaceutical Product is non-hazardous based on chemical classification rules. Avoid direct contact and significant aerosol/dust exposure which has the remote possibilities of eliciting an allergic respons. May cause sensitization of susceptible persons. This material is not likely to be significantly absorbed via occupational routes of entry due to its chemical structure and large molecular weight. Accidental injection may cause effects similar to those seen in clinical use and mentioned in the patient packaging insert. Refer to the pharmacotherapeutic group (section 1.2) and the patient packaging insert to evaluate the possible workplace hazards when this Finished Pharmaceutical Product is accidently leaking, broken or crushed.
Ingredient(s) with unknown acute toxicity
16.42 %
2.1 Classification of the substance or mixture
Not a hazardous substance or mixture.
